Zypitamag™ (pitavastatin) – New drug approval
July 14, 2017 – The FDA approved Zydus Pharmaceuticals’ Zypitamag (pitavastatin) for patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
Top